Continuous Glucose Monitoring (CGM) Market

CONTINUOUS GLUCOSE MONITORING (CGM) MARKET OVERVIEW

Continuous Glucose Monitoring (CGM) Market was valued at USD 15.65 billion in 2024 and is expected to reach USD 16.55 billion in 2025, growing to USD 26.55 billion by 2033, with a CAGR of 5.7% during the forecast period.

The market for continuous glucose monitoring, or CGM, is expanding quickly and steadily because to the growth in diabetes diagnoses worldwide and growing recognition of the need of real-time glucose data for better diabetes management. In order to give consumers and clinicians real-time glucose information, including patterns, trends, and high and low glucose alarm signals, CGM devices help track under-the-skin sensors that continually monitor blood glucose levels.

Technological advances are pushing the market towards increasingly integrated, precise, and convenient products. Smaller size and minimally invasive sensors, increased wear time of sensors, user-friendliness in interacting with insulin pumps and smartphones, and development of sophisticated algorithms for predictive alarms and customized information are the advancements. Its ability to deliver an overall perspective on glucose variability is one of the key drivers of increasing acceptance. This makes better control of glycaemia, less hypoglycaemia, and an improved life for diabetic patients.

COVID-19 IMPACT: 

"Continuous Glucose Monitoring (CGM) Industry Had a Negative Effect Due to supply chain disruption during COVID-19 Pandemic"

The global COVID-19 pandemic has been unprecedented and staggering, with the CGM market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth being significantly accelerated by the pandemic.

The COVID-19 pandemic benefited the Continuous Glucose Monitoring (CGM) market by amplifying the immediate demand for remote patient monitoring and enabling improved glycemic management in patients with diabetes. Lockdowns and quarantines kept people from visiting healthcare facilities in person, further relying on remote monitoring solutions such as CGM to enable care providers to remotely monitor patients' blood glucose levels. The FDA also broadened the in-hospital use of CGM devices during the pandemic. Financial uncertainty did not divert patient expenditures away from vital medical technology such as CGM; in reality, emphasis on controlling underlying health conditions such as diabetes that raised the stakes for severe COVID-19 likely stimulated higher adoption. The pandemic did not affect "cultivation" of CGM since it is a healthcare device but brought to the fore its pivotal role in diabetes management during a health emergency, hence stimulating market growth.

LATEST TREND

"Technological Innovation, Growing Applications, and Digital Integration Defining the CGM Market"

The trend in the Continuous Glucose Monitoring (CGM) market has been marked by fast-paced technological innovation, accelerated adoption by consumers outside intensive insulin therapy, and greater integration with digital healthcare platforms. One of the key trends is the introduction of real-time CGM (rt-CGM) systems with continuous glucose monitoring without the requirement for periodic fingerstick calibration, enhancing user convenience and compliance. Major breakthroughs are long wear times for sensors (10-14 days), smaller and less conspicuous sensor sizes, and better accuracy of glucose readings. Strong focus is also on integration with smartwatches and smartphone apps for real-time visualization, personalized notification, and effortless sharing with caregivers and healthcare providers. The emergence of interoperable CGM systems that can automatically exchange data directly with automated insulin delivery (AID) systems (artificial pancreas) is the key driver, resulting in increasingly automated and accurate glucose control. Additionally, the market is also seeing growing use of CGM by patients with non-insulin-dependent diabetes and even for general wellness monitoring in certain settings, reflecting the broadening applications of this technology. Study of non-invasive CGM technology continues to be a major topic for ongoing development.

CONTINUOUS GLUCOSE MONITORING (CGM) MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into Transmitters, Sensors, Insulin Pumps

• Sensors: These are the basic component of CGM systems, implanted subcutaneously to measure glucose concentration in interstitial fluid on a continuous basis. They have a limited lifespan (e.g., 7-14 days) and require replacement from time to time. Advancement in sensor technology is towards greater accuracy, longer wear duration, and miniaturization for enhanced user comfort.

• Transmitters: This device is mounted on the sensor and wirelessly transmits the glucose information to a receiver or a smart device compatible with it. There are CGM systems in which there is a reusable separate transmitter, while in some, the transmitter is built into the disposable sensor. Reliable data transmission and battery life are the major characteristics of these.

• Insulin Pumps: Insulin pumps are frequently used in conjunction with CGM to produce automatic insulin delivery (AID) systems, sometimes known as artificial pancreas systems, even though they are not a direct part of CGM systems. Insulin pumps are tiny, electronic devices that replicate the actions of a functioning pancreas by delivering insulin continuously (basal) and sporadically (bolus). With CGM, real-time glucose monitoring is used to adjust automatic insulin delivery.

By Application

Based on application, the global market can be categorized into Hospitals, Homecare Settings, Others

• Hospitals: This category encompasses the application of CGM systems to monitor glucose in hospitalized patients, especially those on intensive care or in surgery, where strict glycemic control is essential. Hospitals need precise and trustworthy CGM data for effective and timely intervention and management of diabetic or stress-induced hyperglycemic patients.

• Homecare Setting: This is the largest and most rapidly growing category, representing people with diabetes using CGM systems for ongoing self-testing of their blood glucose at home. The growing use in this environment is due to the convenience, detailed data feedback, and better glycemic control provided by CGM over conventional blood glucose monitoring.

• Others: This category can encompass uses in research centers for clinical trials, schools for training healthcare providers, and possibly wellness clinics or sports medicine facilities investigating CGM for individualized health and performance tracking in non-diabetic individuals.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.                         

DRIVING FACTORS

"Growing Incidence of Diabetes and Increased Awareness of Sophisticated Glucose Management to Drive the Market"

The growing worldwide incidence of diabetes, which is influenced by sedentary lifestyles, unbalanced diets, and a population that is increasingly aging, is a major driver of the CGM market growth. At the same time, increased awareness among patients with diabetes, caregivers, and healthcare professionals about the profound benefits of continuous glucose monitoring over standard approaches is contributing to driving the market. This increased sensitivity includes the capacity of CGM to offer real-time glucose trends, alarms for risky highs and lows, and a better perspective on glycemic variability, resulting in proactive and individualized diabetes treatment.

"Technological Developments Causing More Precise, More Convenient, and More Integrated Devices to Make the Market Broader"

The continuous development of technology is a major factor driving the CGM industry. Improved connectivity via Bluetooth and Near-Field Communication (NFC) to facilitate simple data transfer to smartphones, smartwatches, and other digital health platforms, larger, less invasive sensors for increased user comfort and compliance, and sensors with longer wear lives are some examples. Furthermore, CGM systems are becoming incredibly important assets for both patients and healthcare professionals due to the integration of sophisticated algorithms and artificial intelligence to evaluate data, provide personalised insights, and deliver predictive alerts.

RESTRAINING FACTOR

"High Cost and Limited Reimbursement in Most Regions to Potentially Slow Down Market Growth"

The relatively high price of CGM devices, both the initial system cost and the recurring cost of replacement sensors and transmitters, continues to be a major impediment to broader use, especially in areas with less extensive healthcare coverage or lower socioeconomic status. Restrictive or erratic reimbursement policies by insurance companies and government healthcare programs in most nations further widen this gap, limiting coverage of CGM to a large section of the population with diabetes who would gain from it. Resolving the issue of affordability and access of CGM through enhanced reimbursement schemes is key to unleashing its total market potential.

OPPORTUNITY

"Interconnection with Artificial Intelligence and Extension of Applications Outside of Diabetes to Provide Opportunities"

The growing use of CGM data with machine learning and AI algorithms offers tremendous potential for proactive and personalized management of diabetes. AI can use the continuous glucose data to find patterns, forecast glucose excursions, and make personalized recommendations regarding insulin dosing, diet, and exercise. Outside of diabetes, the use of CGM technology is expanding to include such areas as management of gestational diabetes, glucose monitoring in intensive care, and even wellness apps for athletes and those interested in optimizing their metabolic well-being and performance. Investigations into non-invasive CGM technologies also hold the potential for transformation in the future.

CHALLENGE

"Making Data Secure, Interoperable, and Educating Users to Facilitate Widespread Adoption Might Be Potential Challenges"

As CGM devices become more connected and produce sensitive personal health information, maintaining strong cybersecurity practices and safeguarding patient privacy are key challenges. Seamless interoperability between various CGM systems, insulin pumps, and an expanding set of digital health platforms is still a technical and regulatory challenge. In addition, proper user education and training of both patients and health professionals are needed to ensure optimal and proper use of CGM technology, accurately interpret the data, and incorporate it into diabetes care plans for effective and useful adoption on a large scale.

CONTINUOUS GLUCOSE MONITORING (CGM) MARKET REGIONAL INSIGHTS

• 
•  

• North America

The top market in the CGM landscape is North America, with United States continuous glucose monitoring (CGM) market comprising the largest portion of the worldwide market. It owes this prevalence to a widespread incidence of diabetes, robust health infrastructure, sound reimbursement policies, and the established presence of giant market players encouraging technological innovation and uptake. There is a very high adoption rate of real-time CGM devices and growing alignment with digital health platforms and autonomous insulin delivery devices in the US market.

• Europe

Europe is the second-largest continuous glucose monitoring (CGM) market share globally, with major contributions from Germany, France, and the United Kingdom. The continent is aided by well-developed healthcare systems, rising awareness of the advantages of CGM for better diabetes control, and expanding reimbursement coverage in a number of countries. The European market is experiencing a consistent increase in CGM uptake among both type 1 and type 2 diabetes populations, as well as emphasis on user-friendly devices and data integration.

• Asia

Asia-Pacific is the most rapidly developing region in the CGM market, driven by a sharply escalating prevalence of diabetes, rising expenditure on healthcare, and rising awareness among patients regarding more advanced glucose monitoring technology. Economies like China and India, with very large numbers of diabetics, represent promising growth opportunities. Though classical blood glucose measurement is still more cost-conscious in some areas, application of CGM is steadily on the rise through the help of technology-based improvements decreasing cost and accessibility of equipment, as well as intensifying government initiative towards improved care of diabetes.

KEY INDUSTRY PLAYERS

"Dominant Industry Players Steering the Market With Innovation and Market Growth"

Large business players are dominating the Continuous Glucose Monitoring (CGM) market by driving business innovation and expansion. These large business players are prominent medical device manufacturers with experience in diabetes management, i.e., Abbott, Dexcom, Medtronic, and Roche. These firms dominate developing and selling next-generation CGM systems with enhanced precision, usability, and integration with digital platforms and insulin pumps. These firms are aggressively investing in R&D to create next-generation CGM technologies that incorporate longer-life sensors, compact and less obtrusive designs, and advanced algorithms for customized analysis and predictive alert. They also plan to expand their global market reach, improve supply chain efficiency, and strategic partnerships to expand their product portfolio and coverage. Through ongoing innovation and responsiveness to the changing needs of people with diabetes, these corporate behemoths are fueling growth and dictating trends in the CGM market.

List of Top Companies 

• Pfizer (U.S.)
• Baxter (U.S.)
• Abbott Laboratories (U.S.)
• Medtronic (U.S.)
• Animas (U.S.)
• Novo Nordisk (Denmark)
• Ypsomed (Switzerland)
• GlySens (U.S.)

KEY INDUSTRY DEVELOPMENT

March and June 2024: The FDA approved some Over-the-Counter (OTC) Continuous Glucose Monitoring (CGM) systems, such as Stelo by Dexcom and Lingo and Libre Rio by Abbott. These clearances represent a major extension of CGM availability, permitting adults aged 18 and older who do not take insulin to buy and use these devices without a prescription, largely for general health and an enhanced awareness of their metabolic reaction to diet and exercise. This action has the ability to empower a wider population to actively take control of their health and learn about their glucose levels beyond conventional diabetes care.

REPORT COVERAGE

The research includes a detailed SWOT analysis and gives insights into future trends within the Continuous Glucose Monitoring (CGM) market. It discusses several factors contributing to market growth, touching upon a vast array of market segments and prospective uses that are likely to affect its path over the next few years. The analysis considers both the existing trends and past turning points, giving a complete picture of the components of the market and pinpointing possible areas of expansion.

The Continuous Glucose Monitoring (CGM) marketplace is currently seeing a dramatic and increasing boom fueled by the growing international burden of diabetes, intense technological innovation in sensor precision and convenience to the user, and expanding acceptance of the clinical value of real-time glucose information for enhanced diabetes control. In spite of issues like the cost of devices being high and wider reimbursement, the market demand for CGM systems is robust in different patient groups and across numerous healthcare settings. Industry leaders are the driving force behind innovation, creating more integrated, easier-to-use, and interoperable CGM products. As personalized diabetes care and remote monitoring grow more intense, and in conjunction with the new availability of over-the-counter CGMs to an expanding base of wellness-oriented consumers, the market for CGMs is likely to see continued strong growth fueled by ongoing technological innovation and rising access.